We hypothesized that in AML consolidation therapy, such innovative G-CSF schedules have the potential to substantially reduce the nadir and the duration of leukopenia and may significantly improve the outcome of AML treatment. This evidence concerns the gene CSF3 and Decreased total leukocyte count.